Climb Bio (NASDAQ:CLYM) Director Purchases $24,888.50 in Stock

Climb Bio, Inc. (NASDAQ:CLYM) Director Ra Capital Management, L.P. purchased 7,111 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average cost of $3.50 per share, for a total transaction of $24,888.50. Following the completion of the acquisition, the director owned 3,403,429 shares in the company, valued at $11,912,001.50. This represents a 0.21% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, December 12th, Ra Capital Management, L.P. acquired 101,462 shares of Climb Bio stock. The shares were bought at an average cost of $2.86 per share, with a total value of $290,181.32.
• On Thursday, December 11th, Ra Capital Management, L.P. acquired 213,099 shares of Climb Bio stock. The shares were bought at an average price of $2.18 per share, for a total transaction of $464,555.82.

Climb Bio Price Performance

Shares of CLYM stock traded up $0.39 during mid-day trading on Wednesday, hitting $4.20. The company had a trading volume of 631,508 shares, compared to its average volume of 744,267. The stock’s 50 day moving average price is $2.72 and its 200-day moving average price is $2.15. Climb Bio, Inc. has a 52-week low of $1.05 and a 52-week high of $5.05. The company has a market capitalization of $286.36 million, a P/E ratio of -5.53 and a beta of -0.16.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). On average, equities research analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on CLYM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of Climb Bio in a research report on Thursday, October 16th. HC Wainwright boosted their price target on shares of Climb Bio from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Wall Street Zen downgraded shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. Finally, William Blair began coverage on shares of Climb Bio in a research note on Thursday, October 16th. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.50.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new position in shares of Climb Bio during the first quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Climb Bio during the third quarter worth $29,000. Qube Research & Technologies Ltd bought a new stake in Climb Bio during the 2nd quarter valued at $43,000. Marshall Wace LLP bought a new stake in Climb Bio during the 2nd quarter valued at $46,000. Finally, Prelude Capital Management LLC purchased a new position in shares of Climb Bio in the 3rd quarter valued at $82,000. 69.76% of the stock is currently owned by institutional investors.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.